Trudeau Institute researchers played a key role in confirming the effectiveness of two approaches to fighting the novel coronavirus, according to a pair of papers published this winter.
Both projects relied on pre-clinical studies carried out at Trudeau on behalf of the Walter Reed Army Institute of Research (WRAIR), which developed the vaccine and treatment. One, which tested a new COVID-19 vaccine, was published in Cell Reports. The other, which tested a monoclonal antibody treatment aimed at infected individuals, was published in Nature Immunology.
WRAIR is a leading researcher of diseases such as malaria, HIV/AIDS, Ebola and dengue. It relied on Trudeau’s laboratory expertise to verify the effectiveness of the vaccine and treatment before moving to clinical trials.
“We have really extensive experience and knowledge of how to work with pathogens,” said William Reiley, Ph.D., head of research services at Trudeau. “Since the start of the coronavirus epidemic, we’ve been developing models to conduct preclinical, early developmental stage testing of vaccines, therapeutics and monoclonal antibodies.”